期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 201, 期 4, 页码 673-681出版社
WILEY
DOI: 10.1111/bjh.18689
关键词
asparaginase activity; NK-T cell lymphoma; non-Hodgkin lymphoma; radio-chemotherapy
类别
We conducted a retrospective multi-center study to evaluate the efficacy of the MGAD regimen combined with 'sandwich' radiotherapy in patients with localized extranodal NK/T-cell lymphoma. The results showed high rates of complete remission and favorable progression-free and overall survival at 2 and 5 years. However, a significant proportion of patients experienced relapse and there were manageable side effects. Monitoring of asparaginase activity revealed drug inactivation in a considerable number of patients. Short-term MGAD chemoradiotherapy appears to be a viable treatment option for newly diagnosed patients with localized extranodal NK/T-cell lymphoma.
Extranodal NK/T-cell lymphoma, nasal type is a rare and aggressive form of lymphoma, historically associated with poor prognosis. We report here the results of a retrospective multi-centre study evaluating the efficacy of MGAD (methotrexate, gemcitabine, L-asparaginase and dexamethasone) regimen (two cycles) combined with 'sandwich' radiotherapy in 35 patients with localised newly diagnosed extranodal NK/T-cell lymphoma. Thirty-two patients (91%) reached complete remission. With a long median follow-up of 59.6 months, progression-free and overall survival at 2 and 5 years were 71%, 80% and 53%, 73%, respectively. Around one third of the patients experienced relapse within a median time of 14.5 months. Side-effects were manageable with grades 3-4 cytopenias, mucositis and infection in 50%, 24% and 21% of the cases, respectively. Monitoring of asparaginase activity was performed in 13 patients and showed inactivation of the drug in seven (54%) patients. Our results indicate that a short therapy by sandwich MGAD chemoradiotherapy is a tolerable and effective treatment option in localised newly diagnosed extranodal NK/T-cell lymphoma patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据